Aridis Pharmaceuticals, Inc. Stock price

Equities

ARDS

US0403341045

Biotechnology & Medical Research

Market Closed - OTC Markets 02:49:09 2024-03-28 pm EDT 5-day change 1st Jan Change
0.078 USD +4.35% Intraday chart for Aridis Pharmaceuticals, Inc. +5.41% +11.27%
Sales 2023 * 21.4M Sales 2024 * 7.6M Capitalization 3.74M
Net income 2023 * 4M Net income 2024 * -4M EV / Sales 2023 * 0.17 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 0.49 x
P/E ratio 2023 *
1.11 x
P/E ratio 2024 *
-0.87 x
Employees 37
Yield 2023 *
-
Yield 2024 *
-
Free-Float 81.2%
More Fundamentals * Assessed data
Dynamic Chart
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023. CI
Certain Warrants of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023. CI
Certain Pre-Funded Warrant of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023. CI
Certain Common Stock of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023. CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Aridis Pharmaceuticals, Inc. Announces Resignation as Chief Financial Officer CI
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from S&P TMI Index CI
Sector Update: Health Care Stocks Steady Premarket Tuesday MT
Aridis Pharmaceuticals, European Regulator Agree on Pneumonia Phase 3 Study Parameters; Shares Jump Premarket MT
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from NASDAQ Composite Index CI
Aridis Pharmaceuticals Reaches Agreement for Phase 3 Study of Pneumonia Treatment in Europe; Shares Jump After Hours MT
Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and A Single Confirmatory Phase 3 Study of AR-301 CI
Aridis Pharma Shares Rise 33% After FDA Product Designation for AR-301 DJ
Aridis Pharmaceuticals Gets FDA Product Designation for AR-301 DJ
More news
1 day+4.35%
1 week+5.41%
Current month+1.04%
1 month+1.30%
3 months+14.71%
6 months-17.37%
Current year+11.27%
More quotes
1 week
0.07
Extreme 0.0715
0.08
1 month
0.07
Extreme 0.071
0.09
Current year
0.06
Extreme 0.063
0.09
1 year
0.05
Extreme 0.05
0.54
3 years
0.05
Extreme 0.05
7.72
5 years
0.00
Extreme 0
12.40
10 years
0.00
Extreme 0
13.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 02-12-31
Founder 75 02-12-31
Director of Finance/CFO 57 -
Members of the board TitleAgeSince
Director/Board Member 79 15-03-31
Founder 75 02-12-31
Chief Executive Officer 60 02-12-31
More insiders
Date Price Change Volume
24-03-28 0.078 +4.35% 18,884
24-03-27 0.0748 +0.88% 35,280
24-03-26 0.0741 -4.88% 5,811
24-03-25 0.0779 -0.13% 43,293
24-03-22 0.078 +5.41% 16,538

Delayed Quote OTC Markets, March 28, 2024 at 02:49 pm EDT

More quotes
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The Company's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Company's clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.078 USD
Average target price
2 USD
Spread / Average Target
+2,464.10%
Consensus
  1. Stock
  2. Equities
  3. Stock Aridis Pharmaceuticals, Inc. - OTC Markets